As shown in Table S3, of 107 AML patients with intermediate and adverse-cytogenetic risk, IPM-HR was significantly related to RUNX1 mutation (P = 0.023) and advanced age (P < 0.0001). This evidence concerns the gene RUNX1 and acute myeloid leukemia.